Decentralized Clinical Studies: Complete Guide 2025

Clinical research is undergoing a massive transformation. For decades, participating in a trial meant frequent, often burdensome, trips to a central hospital or clinic. But today, a more flexible, patient friendly model is taking center stage. Welcome to the world of decentralized clinical studies, a modern approach that brings research directly to the participant, wherever they are.

This shift isn’t just about convenience. It’s about creating more inclusive, efficient, and realistic studies that can accelerate the development of new treatments. Let’s dive into what decentralized clinical studies are, how they work, and why they represent the future of medical research.

What Are Decentralized Clinical Studies?

A decentralized clinical trial (DCT) is a study where some or all of the activities happen away from a traditional research site. Instead of requiring participants to travel to a specific clinic for every appointment, these studies leverage technology and local services to conduct research in or near a participant’s home.

The U.S. Food and Drug Administration (FDA) supports this model, defining it as a trial where activities occur at locations other than traditional clinical trial sites. This patient centric approach uses tools like telemedicine for virtual visits, local labs for blood tests, and even home health services for certain procedures, all powered by modern decentralized clinical trial technology. The goal is simple: reduce the geographic and travel barriers that often prevent people from participating in research.

The Rise of Pragmatic and Hybrid Models

Not all decentralized clinical studies are the same. The concept has evolved to include different models that balance remote activities with real world needs.

Decentralized Pragmatic Clinical Trials

A pragmatic clinical trial tests a new treatment under real world conditions with a broad patient population. When you combine this with decentralized methods, you get a study that integrates seamlessly into a participant’s daily life. This approach enhances pragmatic trials by reaching more diverse participants and collecting data from their normal environments.

A great example is the ADAPTABLE trial for heart disease. This study was conducted almost entirely remotely. Researchers identified patients through electronic health records, enrolled them using an online portal for consent, and had them report outcomes online. By meeting patients where they are, these trials produce results that are more applicable to everyday medical care.

Understanding Decentralized Trial Elements

It’s important to know that very few studies are 100% remote. Most are hybrid, meaning they mix decentralized activities with some traditional site visits. In fact, a recent analysis found that nearly 98% of studies with decentralized components used a hybrid model.

Common decentralized elements include:

• Electronic Informed Consent (eConsent): Signing consent forms digitally on a tablet or computer.
• Telehealth Visits: Conducting follow up appointments via video calls.
• Remote Monitoring: Using wearable sensors or smartphone apps to collect health data automatically.
• Local Facilities: Allowing participants to visit nearby labs or imaging centers for tests.
• Direct to Patient Shipments: Mailing study medications directly to a participant’s home.
• Mobile Health Providers: Sending nurses or phlebotomists to a participant’s home for procedures like blood draws.

Sponsors can mix and match these elements to design a trial that is both scientifically rigorous and convenient for participants.

The Tech Powering Modern Clinical Research

Technology is the engine that makes decentralized clinical studies possible. From simple apps to sophisticated sensors, digital tools are changing how research is done.

Digital Health Technologies (DHTs) Explained

Digital health technologies (DHTs) are the tools and platforms that enable remote data collection and communication. This includes everything from wearable sensors that track your heart rate to smartphone apps for tracking symptoms. As of 2020, around 460 clinical trials were already using wearables or sensors to gather patient data.

In a decentralized study, you might use:

• A smartwatch that sends activity data to the research team.
• A mobile app to record your symptoms in an electronic diary (eDiary).
• A video conferencing platform to talk with the study doctor.

These technologies can capture data more frequently and objectively, providing a richer picture of a participant’s health.

Digital Health Technology Selection and Use

Choosing the right DHT is critical for a study’s success. The selection should be driven by the specific data you need to measure, not just the technology itself. Key considerations include the trial population’s technical comfort, the device’s validation and accuracy, and its ease of use. Before full deployment, it is a best practice to conduct feasibility testing to ensure the technology works as expected in a real world environment and to develop a management plan for issues like device failure or replacement.

Digitization vs. Digital Transformation

It’s useful to understand the difference between two key terms: digitization and digital transformation.

Digitization is about converting manual processes into a digital format. For example, replacing a paper consent form with a digital version on a tablet is digitization. It’s an important first step.

Digital Transformation, on the other hand, is about fundamentally redesigning how a trial is conducted using digital tools. This could mean using real time data from wearables to replace some clinic visits entirely or using AI to spot safety issues faster. It’s not just about doing old things on a screen; it’s about using technology to do new things that improve the entire research process.

Platforms like the one offered by Curebase are built to enable this true digital transformation, integrating everything from eConsent and remote data capture with an integrated EDC to site coordination into a single, intelligent system.

A Catalyst for Change: The COVID 19 Impact

The COVID 19 pandemic was a major turning point for decentralized clinical studies. With lockdowns and travel restrictions, traditional research came to a halt. In early March 2020, over 500 companies had announced disruptions to their clinical trials.

In response, researchers and regulators quickly adopted remote solutions. The FDA issued emergency guidance encouraging virtual visits, remote monitoring, and direct to patient drug shipping to keep studies going safely. This forced pivot proved that large scale remote research was possible. The number of new trials with decentralized elements jumped by 50% in 2021 compared to 2020. What was once a niche concept became a mainstream necessity, compressing years of change into just a few months.

Roles and Responsibilities in a Decentralized Model

While DCTs offer flexibility, they also require clear definitions of roles and responsibilities to maintain regulatory compliance and oversight.

Sponsor Role and Responsibility

In a decentralized trial, the sponsor’s fundamental responsibilities remain the same, but the execution changes. The sponsor is ultimately responsible for ensuring the trial is conducted according to the protocol and legal requirements. This includes developing robust plans for all decentralized elements, managing data from diverse sources, overseeing the investigational product supply chain, and implementing a risk based monitoring strategy. Sponsors must also ensure that any third party vendors are properly vetted and managed.

Investigator Role and Delegation

The principal investigator (PI) retains ultimate responsibility for the trial’s conduct and the supervision of all delegated tasks. The key difference in a DCT is the increased reliance on remote personnel and local healthcare providers (HCPs). The PI must ensure that any delegated activities are performed by qualified individuals and are conducted according to the protocol. This includes providing clear instructions to local HCPs to minimize data variability and regularly reviewing the data they provide.

Third Party Collaborator Oversight

DCTs often rely on a network of collaborators, from mobile nursing services to technology platform vendors. Sponsors and investigators must have formal agreements that clearly define the roles, responsibilities, and training requirements for each partner. Rigorous vetting and ongoing oversight of these third parties are essential to maintain data integrity and participant safety.

Putting People First: Engagement and Accessibility

The ultimate goal of decentralized clinical studies is to make research more accessible and human centric. This requires a focus on strong participant engagement and thoughtful design for diverse communities.

Participant and Community Engagement

Without regular face to face visits, keeping participants motivated and informed is critical. One study comparing a decentralized model to a traditional one for back pain found the decentralized group had much better results. They enrolled patients faster and saw 89% of participants complete the study, compared to only 60% in the traditional group.

Successful engagement often involves partnering with trusted local organizations. For example, the BeatPain Utah trial worked with 13 community health centers in rural Utah to deliver its program via telehealth. This community based approach builds trust and improves outreach. At Curebase, our OmniSite™ model does just this, activating community clinics, local pharmacies, and other trusted locations to make research a part of everyday healthcare. Learn how Curebase brings trials into the community.

Special Considerations for Diverse Populations

Decentralized trials have huge potential to include populations often left out of research, like older adults, people with rare diseases, or those in rural areas. However, technology can also be a barrier. For instance, nearly 46% of adults over 65 in the UK lack basic internet skills.

A truly inclusive study must be flexible. This might mean providing training, offering low tech options like phone calls, or ensuring apps have features like larger text for accessibility. When designed thoughtfully, decentralization is a powerful tool. In fact, between 2018 and 2022, trials enrolling only seniors were 1.5 times more likely to use decentralized components than trials overall.

Rare Disease Considerations

Traditional clinical trials are particularly challenging for patients with rare diseases, who are often geographically scattered. DCTs help overcome these geographic barriers, reducing the burden of travel and making it easier for patients to participate from home. This approach can improve recruitment, retention, and the diversity of the patient population, ultimately accelerating the development of treatments for these conditions.

Community Health and Bridging the Digital Divide

To be effective, decentralized clinical studies must consider the health context of the communities they aim to serve. Rural areas, for example, often have higher rates of illness and less access to healthcare, making them prime candidates for the benefits of remote trials.

But researchers must address the digital divide. Do participants have reliable internet? Are they comfortable with technology? Successful studies plan for this. The GRACE trial, for instance, provided participants with tablets, data plans, and even transportation vouchers to ensure no one was excluded due to a lack of resources.

Ensuring Quality and Compliance in Decentralized Research

Just because a trial is remote doesn’t mean the standards are lower. Regulatory oversight, robust safety planning, and data security are paramount. The same FDA regulations apply to both decentralized and traditional trials.

FDA and IRB Oversight

The FDA has provided guidance confirming that DCTs are subject to the same regulatory requirements as traditional site based trials. The guidance emphasizes the need for risk based approaches to monitoring, ensuring data integrity, and protecting participants. Similarly, Institutional Review Boards (IRBs) play a crucial role in overseeing DCTs. They review protocols and consent forms to ensure participant rights and welfare are protected, paying special attention to aspects like remote consent processes and data privacy. Using a central IRB is often recommended to streamline review for multi location trials.

Safety Monitoring Plan

Every DCT must have a comprehensive safety monitoring plan that is adapted for the remote environment. This plan should detail how adverse events will be captured, reported, and managed when participants are not physically at a study site. It should specify procedures for both routine safety data collection (through telehealth or local HCPs) and for urgent issues, ensuring participants know who to contact and where to seek care if needed.

Investigational Product Management

Managing the investigational product (IP) in a DCT requires careful planning for direct to patient logistics. The sponsor and investigator are responsible for the entire supply chain, from packaging and labeling to shipping and accountability. Drugs best suited for DCTs typically have strong stability profiles. Robust procedures must be in place to track shipments, ensure proper storage conditions (like temperature control), and manage the return of unused products.

Privacy, Confidentiality, and Data Security

With data being collected remotely and transmitted digitally, protecting participant privacy is a top priority. DCTs must implement strong security measures, such as end to end encryption for data in transit and at rest, multi factor authentication, and secure cloud platforms. Protocols should use data anonymization and de-identification techniques whenever possible to protect participant identities. Compliance with regulations like HIPAA and GDPR is essential to build trust and ensure the integrity of the trial.

Electronic System and Software Compliance

The electronic systems and software used in DCTs, including ePRO apps and integrated platforms, must comply with regulatory standards like the FDA’s 21 CFR Part 11. This ensures that electronic records and signatures are trustworthy, reliable, and equivalent to paper records. Key requirements include secure access controls, audit trails to track all data changes, and system validation to confirm that the technology performs as intended.

The Evolving Landscape of Decentralized Clinical Studies

The field of decentralized research is constantly evolving. After a period of rapid growth, the industry is now in a phase of refinement.

Trends and Trajectory

The pandemic triggered a boom, with the number of new trials using decentralized components expected to reach around 1,300 in 2022. The market for these solutions continues to grow, with forecasts predicting a compound annual growth rate of about 7.6% through 2033.

We are also seeing major collaborations, like Walgreens partnering with the U.S. government to conduct trials in community pharmacies. This, along with formal guidance from the FDA in 2023, shows that decentralized methods are becoming a standard part of the research toolkit.

Why Some Decentralized Trials are Declining or Pausing

After the initial hype, there was a noticeable drop in the number of new DCTs started after 2021. Some early studies also had lower completion rates; for example, only 72% of DCTs were completed in 2020, down from 87% in 2016.

This doesn’t mean the model is failing. Rather, it reflects a period of learning and recalibration. Many early attempts were poorly designed or rushed, leading to operational issues. The industry is now moving away from a “one size fits all” mentality and toward a more thoughtful, hybrid approach. Completion rates have been steadily improving since the pandemic as best practices emerge.

The Reality of Limited Incorporation

Today, most sponsors use a hybrid model, incorporating only one or two decentralized elements. Why not more? Reasons include:

• Protocol Needs: Some procedures, like complex infusions or surgeries, must be done in person.
• Organizational Habits: Research teams are often accustomed to traditional methods and may be slow to adopt new workflows.
• Operational Complexity: Coordinating a network of local providers can be more difficult than working with a few large research centers.
• Technology Integration: Juggling multiple disconnected software systems can be a headache.

This cautious approach is understandable. The industry is finding a sustainable balance, using remote tools where they add the most value.

Solutions for Successful Decentralized Trial Implementation

Implementing decentralized clinical studies can be complex, but proven solutions can ensure success.

1. Early Planning and Protocol Design: Build decentralized methods into your trial from the very beginning. A well planned protocol avoids confusion and ensures every part of the study is designed for a remote or hybrid setting.
2. Integrated Technology Platforms: Use a single, unified platform to manage all digital trial components. An integrated system simplifies operations for sponsors, sites, and participants.
3. Participant Support and Training: Provide clear instructions, training materials, and a dedicated helpdesk to support participants. Supplying devices or ensuring low tech options are available can prevent people from dropping out.
4. Home Healthcare and Local Partnerships: Use mobile nurses for at home procedures and partner with local pharmacies and clinics to create convenient touchpoints for participants, supported by streamlined patient recruitment and prescreening. This model has been shown to dramatically increase the inclusion of older patients in research.
5. Robust Quality Management: Implement remote monitoring tools and risk based quality assurance to maintain oversight. Real‑time reporting dashboards can help spot issues faster than in a traditional trial.
6. Partner with an Experienced Provider: Leverage the expertise of companies that specialize in decentralized clinical studies. An experienced partner can provide the technology, operational support, and regulatory know how to get your study right from day one.

At Curebase, we provide an end to end solution that combines an AI native eClinical platform with flexible site models and expert services. We handle the complexity so you can focus on the science. See how our platform and services can power your next study.

Frequently Asked Questions about Decentralized Clinical Studies

What is the main benefit of a decentralized clinical study?

The main benefit is making research more accessible and convenient for patients. By reducing the need for travel, decentralized clinical studies can attract a more diverse group of participants, speed up recruitment, and improve retention.

Are decentralized clinical studies safe?

Yes. They must meet the same rigorous safety and ethical standards as traditional trials. Protocols include plans for safety monitoring, managing adverse events remotely, and ensuring participants can always contact the research team.

What technology is used in these studies?

Common technologies include smartphone apps for reporting symptoms (ePRO/eCOA), wearable sensors (like smartwatches), telemedicine platforms for video visits, and digital tools for signing consent forms (eConsent).

Can I participate in a decentralized study from home?

Often, yes. Many decentralized studies are designed so you can participate entirely from home or with minimal visits to a local clinic. This depends on the specific requirements of the study protocol.

How is data quality ensured in decentralized clinical studies?

Data quality is ensured through several methods, including using validated digital health technologies, training participants on how to use devices correctly, real time data monitoring to spot errors, and remote verification of data by the study team.

What is a hybrid clinical trial?

A hybrid trial combines elements of both traditional, site based trials and decentralized trials. For example, a participant might have an initial visit at a clinic but conduct all follow up visits remotely via video call. The vast majority of modern decentralized clinical studies use a hybrid model.

Do all clinical trials need to be decentralized?

No. While decentralization offers many benefits, it’s not the right fit for every study. Trials involving complex medical procedures or specialized equipment may still require in person visits to a central research site. The best approach is often a hybrid model tailored to the study’s specific needs.